(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of -8.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Xencor's revenue in 2025 is $146,929,000.On average, 6 Wall Street analysts forecast XNCR's revenue for 2025 to be $8,697,702,814, with the lowest XNCR revenue forecast at $7,584,492,712, and the highest XNCR revenue forecast at $10,113,607,923. On average, 6 Wall Street analysts forecast XNCR's revenue for 2026 to be $6,923,684,690, with the lowest XNCR revenue forecast at $5,919,812,818, and the highest XNCR revenue forecast at $10,271,945,085.
In 2027, XNCR is forecast to generate $9,158,093,076 in revenue, with the lowest revenue forecast at $7,284,222,688 and the highest revenue forecast at $12,840,287,971.